pharma.economictimes.indiatimes

Patient group oppose Trehan’s place on Panel reviewing Pharma marketing Code

The inclusion of Dr. Naresh Trehan in a pharmaceutical marketing review panel faces backlash from patient groups over ...
pharma.economictimes.indiatimes

Sun Pharma’s Unolxcyt shows lasting cancer control in long-term follow-up

Sun Pharma's Unolxcyt shows a significant objective response rate and durable cancer control for patients with advanced skin ...
pharma.economictimes.indiatimes

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson's experimental prostate cancer drug, JNJ-6143, has shown significant tumor shrinkage and reduced PSA levels ...
pharma.economictimes.indiatimes

Amgen drug combined with immunotherapy extends survival in lung cancer trial

A groundbreaking study reveals that Amgen's Imdelltra, when combined with AstraZeneca's immunotherapy Imfinzi, significantly ...
pharma.economictimes.indiatimes

Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal

Zymeworks has entered a global licensing agreement with Roche to develop and commercialize its experimental lung cancer drug ...
pharma.economictimes.indiatimes

Dr Reddy’s set to resume Semaglutide supplies in Q3 after production disruption

Speaking to reporters Dr Reddy’s Laboratories CEO, Erez Israeli said, the company plans to “relaunch” Obeda in Canada in Q3 and has also received approvals to launch the product in 10 other emerging ...
pharma.economictimes.indiatimes

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis presents disappointing data for remibrutinib, its oral multiple sclerosis drug, showing lower than anticipated ...
pharma.economictimes.indiatimes

Dr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit

Dr Reddy's Laboratories has introduced two new generic versions of Ozempic, named Obeda Pro and Obeda Plus, to address supply ...
pharma.economictimes.indiatimes

Centre constitutes three member panel to overhaul Pharma marketing regulations

New Delhi: The Department of Pharmaceuticals (DoP) has constituted a high-level committee to examine the existing regulatory framework governing pharmaceutical companies marketing, engagement with ...